Last reviewed · How we verify

NCT05869968: SCIVAX

SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI

Active, enrolled Last updated 3 April 2026
What this trial tests

trial in Spinal Cord Injuries in 140 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
31 March 2023
Primary endpoint
30 September 2026
31 December 2027

Quick facts

Lead sponsorNorthwell Health
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment140
Start date31 March 2023
Primary completion30 September 2026
Estimated completion31 December 2027
Sites1 location across United States

Conditions studied

Sponsor

Northwell Health — full company profile →

Who can join

Adults 18 to 89, any sex, with Spinal Cord Injuries or Traumatic Spinal Cord Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this observational research study is to better understand immune responses to vaccines against viruses (influenza or SARS-CoV2). The goal is to determine any differences in immune responses to vaccines in uninjured people and in people living with spinal cord injuries, who are typically at increased risk of infections.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Spinal Cord Injuries

Currently open trials in the same condition.

Other Northwell Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05869968.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing